Home
Services
Blog
Company
Contact

Posts Aside Archives | Page 3 of 4 | Double-Helix

Category Archive

Home Archive by category "Posts Aside"

HHS grants patients direct access to laboratory reports

February 3, 2014
By Ken Stineman
One Comment
Blog, Posts Aside

The Department of Health and Human Services (HHS) announced the final rule allowing laboratories to deliver laboratory test reports directly to patients and their “personal representatives.” The rule is scheduled to be published in the Federal Register on February 6th. Under HIPAA, according to the new rule, laboratories that are “Covered Entities” are now required to…

Tagged: CLIA, HHS, HIPAA

NSA appoints first Privacy Officer

January 29, 2014
By Ken Stineman
Leave a Reply
Blog, Posts Aside

The National Security Agency (NSA) has announced that it has named IAPP member Rebecca Richards, CIPP/US, CIPP/G, its first-ever Civil Liberties and Privacy Officer. The NSA announced the appointment in a press release today: http://www.nsa.gov/public_info/press_room/2014/civil_liberties_privacy_officer.shtml Last summer, President Obama had announced several initiatives to regain the public’s trust in the NSA and to make information…

Tagged: Privacy

Personalized Medicine World Conference Recap

January 28, 2014
By Ken Stineman
Leave a Reply
Blog, Posts Aside

Double-Helix spent Monday and Tuesday at the Personalized Medicine multidisciplinary community at the Personalized Medicine World Conference (PMWC) held at the Computer History Museum in Mountain View, CA . Great group of more than 1000 attendees attended this year. Looks like they will need a larger venue for 2015! The PMWC honored the CEO of Illumina,…

Tagged: Personalized Medicine

Renew EU Safe Harbor annually or face FTC penalties

January 23, 2014
By Ken Stineman
Leave a Reply
Blog, Posts Aside

Twelve companies agreed this week to settle Federal Trade Commission (FTC) charges that they falsely claimed they were abiding by the Safe Harbor privacy framework, but had allowed their annual self-certification to lapse. The FTC has made enforcement of the US-EU and US-Swiss Safe Harbor a priority following recent European Commission’s critisicm that enforcement was…

Tagged: FTC, HIPAA, Privacy, Safe Harbor

Dermatology practice settles HIPAA violations for $150k

January 5, 2014
By Ken Stineman
Leave a Reply
Blog, Posts Aside

Health and Human Services (HHS) announced on December 27th that Adult & Pediatric Dermatology, P.C., of Concord, Mass., (APDerm) agreed to settle potential violations of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy, Security, and Breach Notification Rules with the Department of Health and Human Services, with a $150,000 payment. http://www.hhs.gov/ocr/privacy/hipaa/enforcement/examples/apderm-agreement.html What…

Tagged: Breach, HHS, HIPAA

Auto Scaling comes to the AWS Management Console

December 18, 2013
By Ken Stineman
Leave a Reply
Blog, Posts Aside

On December 10th, Amazon announced that the Auto Scaling feature is now easily configurable in the AWS Management Console. Amazon AWS Auto Scaling enables you to automatically launch or terminate Amazon Elastic Compute Cloud (Amazon EC2) instances based on user-defined policies, health status checks, and schedules. You can now create Auto Scaling Groups through the…

Illumina working to expand BaseSpace application ecosystem

December 9, 2013
By Ken Stineman
Leave a Reply
Blog, Posts Aside

Double-Helix spent the day in San Francisco at the Basespace Developers meeting learning about their new initiative for “Native” Basespace applications. http://storify.com/UYG13/basespace-developer-meeting-west-coast-edition BaseSpace is Illumina’s cloud environment for the storage and analysis of Next Generation Sequencing (NGS) data. BaseSpace is hosted in Amazon AWS and the system is used by hundreds MiSeq NGS hardware users. In…

23andMe Suspends Health Related Reporting

December 7, 2013
By Ken Stineman
Leave a Reply
Blog, Posts Aside

As of this week, Mountain View based 23andMe will no longer offer health-related results and reporting from its genetic tests. FDA Warning Letter In response to the U.S. Food and Drug Administration’s warning letter, 23andme announced on Thursday, December 5th: “At this time, we have suspended our health-related genetic tests to comply with the U.S.…

Tagged: DTC, FDA, Genetic Testing, SNP

Cybersecurity Challenges for Medical Devices

December 5, 2013
By Ken Stineman
One Comment
Blog, Posts Aside

Regulatory Guidance The FDA recently published guidance recommending that device manufacturers develop security controls in the design of their products to limit malfunctions resulting from computer viruses and attacks, and maintain the confidentiality, integrity, and availability of the device information. At the same time, the latest HIPAA regulations also require risk assessments and the implementation…

Tagged: Cybersecurity, FDA

Missed Opportunities that can cost you that dream job

December 4, 2013
By Molly Ryan
Leave a Reply
Blog, Posts Aside

Digital content specialist Erin Palmer suggests 7 career search and interviewing tips for the job hunter. It’s critical for the job hunter to do research about themselves and their prospective employer before interviewing for that dream job. Erin suggests common missteps including not googling yourself, not doing enough research about the company, being late for…

InVitae defends right to provide BRCA genetic testing

November 26, 2013
By Ken Stineman
Leave a Reply
Blog, Posts Aside

InVitae Corporation announced on November 26th that it plans to defend its right to provide naturally occurring genetic diagnostic testing and services including BRCA. https://www.invitae.com/en/press/invitae-responds-myriad-genetics-lawsuit/ In a complaint filed in Utah federal court, Myriad claims that InVitae is infringing on 11 patents for products that assess a patient’s risk for breast and other cancers. University…

FDA Clears First NGS System for Clinical Use

November 26, 2013
By Ken Stineman
One Comment
Blog, Posts Aside

The FDA granted premarket clearance for the Illumina MiSeqDx high-throughput, next generation gene sequencing instrument. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm375742.htm This is the first benchmark sequencer designed and validated for the clinical market. The instrument is also CE marked for use internationally. They were able to successfully “benchmark” the performance of the system against a publicly available quality scored…

FDA sends warning letter to 23andMe

November 26, 2013
By Ken Stineman
2 Comments
Blog, Posts Aside

On November 22, 2013 the FDA sent a warning letter to 23andMe: http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm The FDA listed “particularly concerning” intended uses including the assessment of BRCA-related genetic risk and response to drugs such as warfarin. The FDA indicated that 23andMe submitted 510(k) applications in 2012 for several of these conditions but had since failed to address…

NIST Releases preliminary Cybersecurity Framework

November 12, 2013
By Ken Stineman
One Comment
Blog, Posts Aside

The National Institute for Standards and Technology released its preliminary cybersecurity framework to provide guidance to “critical infrastructure owners” Critical infrastructure includes those groups that maintain information relating to health and other areas. The framework describes five Framework Core Functions: Identify, Protect, Detect, Respond, and Recover It also categorizes maturity and adoption into four implementation…

Circulating fetal DNA Patent Invalidated

November 11, 2013
By Ken Stineman
Leave a Reply
Blog, Posts Aside

The U.S. District Court for the Northern District of California sided with Ariosa and invalidated multiple claims in Sequenom’s patent for the detection of fetal cell-free (cffDNA) in the blood-stream of pregnant women. Ariosa Diagnostics had asked the court to declare that its Harmony(tm) non-invasive prenatal test was not infringing on patent no.

1
2
3
4

Double Helix LLC
Double Helix Solutions, LLC
1296 Mayette Ave
San Jose, CA 95125
408.390.6948

Privacy
Terms of Use
Company Overview
Contact Us